Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) jointly announced that HLX11, a pertuzumab biosimilar self‑developed by Henlius and commercialized outside China by Organon, has received registration approval from the Brazilian Health Regulatory Agency (Anvisa) for the treatment of HER2‑positive breast cancer, making it the first pertuzumab biosimilar approved in Brazil.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Anvisa (Brazil) |
| Approval Type | Registration approval |
| Product | HLX11 (pertuzumab biosimilar) |
| Indication | Treatment of HER2‑positive breast cancer |
| Approval Date | 9 Nov 2026 |
| Distinction | First pertuzumab biosimilar approved in Brazil |
| Planned Launch | Brazil and EU in 2027; further regulatory submissions in other markets through 2028 |
Drug Profile & Partnership Structure
- Molecule: HLX11, a biosimilar to pertuzumab, the HER2‑dimerization‑inhibiting monoclonal antibody that is a backbone of HER2‑positive breast cancer therapy.
- Developer: Self‑developed by Shanghai Henlius Biotech, one of China’s leading biosimilar platforms.
- Commercialization Rights: Under a 2022 license and supply agreement, Organon holds exclusive commercialization rights for several Henlius biosimilars — including the pertuzumab biosimilar — in global markets outside China.
- Intellectual Property: Organon has entered into a settlement and license agreement with Genentech, Inc. and its affiliates, clearing the path for commercialization of the product.
Global Regulatory Track Record
| Market | Agency | Approval Date |
|---|---|---|
| United States | U.S. FDA | November 2025 |
| European Union | European Commission | April 2026 |
| Brazil | Anvisa | November 2026 |
Market Impact & Outlook
- Latin American Expansion: Brazil’s approval extends HLX11’s footprint into Latin America’s largest pharmaceutical market, where biosimilar uptake is actively encouraged by public procurement policy and a large HER2‑positive breast cancer patient population.
- First‑Mover Advantage: As the first pertuzumab biosimilar cleared by Anvisa, HLX11 can establish early tender positioning ahead of any follow‑on biosimilar entrants in Brazil.
- Momentum for the Henlius–Organon Alliance: The Brazil win follows U.S. FDA (Nov 2025) and European Commission (Apr 2026) approvals, validating the partnership model of Chinese biosimilar development paired with Organon’s global commercial infrastructure.
- Launch Timeline: The product is scheduled for launch in Brazil and the EU in 2027, with regulatory submissions in additional markets continuing through 2028, pointing to a phased global rollout.
- Biosimilar Category Signal: Sequential major‑market approvals reinforce the maturation of complex monoclonal‑antibody biosimilars, an area historically dominated by small‑molecule generics.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding launch timing, additional regulatory submissions and approvals, and commercial expectations for HLX11. Actual results may differ due to risks including regulatory review outcomes, manufacturing and supply execution, intellectual‑property matters, tender dynamics, and competition in the HER2‑targeted therapy market.-Fineline Info & Tech
